Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome. The discussion centered on diverse treatment strategies for myelodysplastic ...

Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

Bexmarilimab and Vidaza achieved high response rates in higher-risk myelodysplastic syndrome, meeting the phase 2 BEXMAB trial's primary endpoint. The treatment demonstrated a 63% objective response ...

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) - two related blood diseases that disproportionally strike older adults - are notoriously difficult to treat and associated with high ...

DelveInsight's,“ Myelodysplastic Syndrome Pipeline Insights 2025” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It ...

Financial considerations in MDS treatment are discussed. In this segment of the discussion on managing myelodysplastic syndrome (MDS), the focus shifted to the economic implications of MDS management, ...

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published inBlood Neoplasia. The ...